Back to Search
Start Over
Reversibility of capillary density after discontinuation of bevacizumab treatment
- Source :
- Annals of Oncology, 21(5), 1100-1105
- Publication Year :
- 2010
-
Abstract
- BACKGROUND: Vascular endothelial growth factor (VEGF) inhibition is known to decrease capillary density. Decreased capillary density may be the basis for VEGF inhibitor-related side-effects. We investigated whether the effects of bevacizumab on capillary density are reversible. PATIENTS AND METHODS: Capillary density, assessed by sidestream dark field imaging of the mucosal surface of the lip, was measured at baseline, after 6 weeks of bevacizumab treatment and >3 months after discontinuation. Additional measurements included blood pressure (BP) measurements, flow-mediated dilation (FMD), nitroglycerin-mediated dilation (NMD) and aortic pulse wave velocity (PWV). RESULTS: Fourteen patients were included. Seven patients completed measurements at all three predefined time points. Capillary density significantly decreased after 6 weeks of bevacizumab treatment and was reversible after discontinuation of bevacizumab (P = 0.00001 using a general linear model repeated measures test). BP, FMD and NMD remained unchanged. Mean PWV increased after 6 weeks of treatment (P = 0.027) and decreased after bevacizumab discontinuation. Among the six patients with the best response were the three patients showing the clearest decrease in capillary density after 6 weeks of bevacizumab treatment. CONCLUSIONS: Bevacizumab-induced decrease in capillary density is reversible. Noninvasive assessment of capillary density during treatment with antiangiogenic drugs may be useful as a marker of treatment efficacy.
- Subjects :
- Male
Vascular Endothelial Growth Factor A
medicine.medical_specialty
Bevacizumab
Angiogenesis
Urology
Angiogenesis Inhibitors
Blood Pressure
Breast Neoplasms
Antibodies, Monoclonal, Humanized
chemistry.chemical_compound
angiogenesis bevacizumab capillary density hypertension rarefaction vascular endothelial growth factor inhibitor metastatic colorectal-cancer renal-cell carcinoma randomized phase-iii breast-cancer hypertension microcirculation inhibition combination paclitaxel pressure
Medicine
Humans
Pulse wave velocity
Aged
business.industry
Microcirculation
Repeated measures design
Antibodies, Monoclonal
Hematology
Middle Aged
Lip
Discontinuation
Surgery
Capillaries
Vascular endothelial growth factor
Blood pressure
Treatment Outcome
Oncology
chemistry
Capillary density
Female
business
Colorectal Neoplasms
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology, 21(5), 1100-1105
- Accession number :
- edsair.doi.dedup.....d1f23584918741ea9a71295fd040ce07